Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AP 325

Next Previous
Drug Profile

AP 325

Alternative Names: AP-325

Latest Information Update: 11 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algiax Pharmaceuticals
  • Class Amides; Analgesics; Antihyperglycaemics; Imidazoles; Nitriles; Non-opioid analgesics; Pyridines; Pyridones; Small molecules; Triazines
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Neuropathic pain; Type 2 diabetes mellitus
  • Discontinued Spinal cord injuries

Most Recent Events

  • 04 Feb 2025 Adverse events and efficacy data from a phase II CURE trial for Neuropathic pain released by Algiax Pharmaceuticals
  • 17 Dec 2024 The Deutsche Diabetes Forschungsgesellschaft and Algiax Pharmaceuticals completes a phase II trial in Type 2 diabetes mellitus in Germany (NCT05160272)
  • 10 Oct 2024 Algiax Pharmaceuticals completes a phase II CURE trial for Neuropathic pain in Spain, Germany, Czech Republic, Belgium, France, and Italy (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top